MedTrace Logo

Improving Prematurity-Related Respiratory Outcomes at Vanderbilt

NCT01460576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 253

Last updated 2017-05-05

No results posted yet for this study

Summary

The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway and the glutathione pathway. The investigators hypothesize that prematurity-related limitations in the function of these important biochemical pathways contribute to respiratory disease risk over the first year of life.

Conditions

  • Preterm Birth
  • Bronchopulmonary Dysplasia
  • Chronic Lung Disease of Prematurity

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Judy L. Aschner, MD · Albert Einstein College of Medicine; Vanderbilt University School of Medicine

Eligibility

Max Age
7 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01460576 on ClinicalTrials.gov